UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001339
Receipt number R000001626
Scientific Title Prospective randomized Phase II trial in nutritional support for autologous PBSCT Non-synbiotics vs Synbiotics
Date of disclosure of the study information 2008/08/29
Last modified on 2014/01/20 09:51:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective randomized Phase II trial in nutritional support for autologous PBSCT
Non-synbiotics vs Synbiotics

Acronym

NST02

Scientific Title

Prospective randomized Phase II trial in nutritional support for autologous PBSCT
Non-synbiotics vs Synbiotics

Scientific Title:Acronym

NST02

Region

Japan


Condition

Condition

malignant lymphoma or multiple myeloma

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety to use GFO and lactobacilus in patients who receive autologous PBSCT

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Probability of more than grade 3 intestinal regimen related toxicity

Key secondary outcomes

(1) 1-year overall survival and event-free survival
(2) Regimen related toxicity except intestinal toxicity
(3) Engraftment
(4) Infectious diseases
(5) Duration of TPN
(6) Dose and duration of intravenous morphine
(7) Dose of insulin
(8) Hyperglycemia and hypoglycemia
(9) DAO activity


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Intervention: Use of GFO and lactobacillus in patients who receive autologous PBSCT

Interventions/Control_2

Standard : No Use of GFO and lactobacillus in patients who receive autologous PBSCT

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Malignant lymphoma or multiple myeloma who can be candidate for autologous PBSCT
(2) 17<Age<66
(3) ECOG PS <2
(4) No obvious organ failure
(5) They have given written informed consent
(6) Patients who will survive more than 3 months

Key exclusion criteria

(1) History of stem cell transplantation
(2) HIV carrier
(3) Uncontrolled active infectious diseases
(4) Pregnant or lactating
(5) Uncontrolled psychological disorder(6) Allergy for the drugs used for the conditioning regimen
(7) Allergy for GFO or lactobacillus
(8) Patients who do not tolerate the maximal defined conditioning regimen due to organ dysfunction (e.g., reduce MCNU due to pulmonary dysfunction, reduce Carboplatin due to renal dysfunction)

Target sample size

76


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Sung-Won Kim

Organization

National Cancer Center Hospital

Division name

Hematology and Stem Cell Transplantation

Zip code


Address

5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

TEL

03-3542-2511

Email

skim@ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Shigeo Fuji

Organization

NTT West Japan Osaka Hospital

Division name

Department of Hematology

Zip code


Address

2-6-40, Karasugatsuji, Tennoji-ku, Osaka-city, Osaka, 543-8922, Japan

TEL

0667737111

Homepage URL

http://www.ncc.go.jp/jp/

Email

s-fuji@pj8.so-net.ne.jp


Sponsor or person

Institute

National Cancer Center Hospital

Institute

Department

Personal name



Funding Source

Organization

the Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 08 Month 29 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2008 Year 08 Month 01 Day

Date of IRB


Anticipated trial start date

2008 Year 09 Month 01 Day

Last follow-up date

2011 Year 08 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 08 Month 29 Day

Last modified on

2014 Year 01 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001626


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name